Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.

Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, Apolo AB, Daw NC, Hodges HC, Moxey-Mims M, Wei D, Bottaro DP, Staehler M, Karam JA, Rathmell WK, Tannir NM.

Clin Genitourin Cancer. 2019 Feb;17(1):1-6. doi: 10.1016/j.clgc.2018.09.005. Epub 2018 Sep 12.

PMID:
30287223
2.

Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells.

Navas T, Pfister TD, Colantonio S, Aziz A, Dieckman L, Saul RG, Kaczmarczyk J, Borgel S, Alcoser SY, Hollingshead MG, Lee YH, Bottaro DP, Hiltke T, Whiteley G, Takebe N, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH.

PLoS One. 2018 Jun 21;13(6):e0199361. doi: 10.1371/journal.pone.0199361. eCollection 2018.

3.

The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.

Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG; Cancer Genome Atlas Research Network, Spellman PT, Rathmell WK, Linehan WM.

Cell Rep. 2018 Jun 19;23(12):3698. doi: 10.1016/j.celrep.2018.06.032. No abstract available.

4.

The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.

Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG; Cancer Genome Atlas Research Network, Spellman PT, Rathmell WK, Linehan WM.

Cell Rep. 2018 Apr 3;23(1):313-326.e5. doi: 10.1016/j.celrep.2018.03.075. Erratum in: Cell Rep. 2018 Jun 19;23(12):3698.

5.

Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors.

Srivastava AK, Hollingshead MG, Govindharajulu JP, Covey JM, Liston D, Simpson MA, Peggins JO, Bottaro DP, Wright JJ, Kinders RJ, Doroshow JH, Parchment RE.

Mol Cancer Ther. 2018 Mar;17(3):698-709. doi: 10.1158/1535-7163.MCT-17-0552. Epub 2018 Feb 14.

6.

Targeting the hepatocyte growth factor/Met pathway in cancer.

De Silva DM, Roy A, Kato T, Cecchi F, Lee YH, Matsumoto K, Bottaro DP.

Biochem Soc Trans. 2017 Aug 15;45(4):855-870. doi: 10.1042/BST20160132. Epub 2017 Jul 3. Review.

PMID:
28673936
7.

Effective implementation of novel MET pharmacodynamic assays in translational studies.

Srivastava AK, Navas T, Herrick WG, Hollingshead MG, Bottaro DP, Doroshow JH, Parchment RE.

Ann Transl Med. 2017 Jan;5(1):3. doi: 10.21037/atm.2016.12.78. Review.

8.

Hepatocyte growth factor/MET in cancer progression and biomarker discovery.

Matsumoto K, Umitsu M, De Silva DM, Roy A, Bottaro DP.

Cancer Sci. 2017 Mar;108(3):296-307. doi: 10.1111/cas.13156. Review.

9.

A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma.

Yau TCC, Lencioni R, Sukeepaisarnjaroen W, Chao Y, Yen CJ, Lausoontornsiri W, Chen PJ, Sanpajit T, Camp A, Cox DS, Gagnon RC, Liu Y, Raffensperger KE, Kulkarni DA, Kallender H, Ottesen LH, Poon RTP, Bottaro DP.

Clin Cancer Res. 2017 May 15;23(10):2405-2413. doi: 10.1158/1078-0432.CCR-16-1789. Epub 2016 Nov 7.

10.

MET Inhibition in Clear Cell Renal Cell Carcinoma.

Xie Z, Lee YH, Boeke M, Jilaveanu LB, Liu Z, Bottaro DP, Kluger HM, Shuch B.

J Cancer. 2016 Jun 18;7(10):1205-14. doi: 10.7150/jca.14604. eCollection 2016.

11.

Tumor and Plasma Met Levels in Non-Metastatic Prostate Cancer.

Kaye DR, Pinto PA, Cecchi F, Reilly J, Semerjian A, Rabe DC, Gupta G, Choyke PL, Bottaro DP.

PLoS One. 2016 Jun 14;11(6):e0157130. doi: 10.1371/journal.pone.0157130. eCollection 2016.

12.

The hepatocyte growth factor isoform NK2 activates motogenesis and survival but not proliferation due to lack of Akt activation.

Mungunsukh O, Lee YH, Bottaro DP, Day RM.

Cell Signal. 2016 Aug;28(8):1114-23. doi: 10.1016/j.cellsig.2016.05.012. Epub 2016 May 17.

PMID:
27224506
13.

Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays.

Srivastava AK, Hollingshead MG, Weiner J, Navas T, Evrard YA, Khin SA, Ji JJ, Zhang Y, Borgel S, Pfister TD, Kinders RJ, Bottaro DP, Linehan WM, Tomaszewski JE, Doroshow JH, Parchment RE.

Clin Cancer Res. 2016 Jul 15;22(14):3683-94. doi: 10.1158/1078-0432.CCR-15-2323. Epub 2016 Mar 21.

14.

Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma.

Chen F, Zhang Y, Şenbabaoğlu Y, Ciriello G, Yang L, Reznik E, Shuch B, Micevic G, De Velasco G, Shinbrot E, Noble MS, Lu Y, Covington KR, Xi L, Drummond JA, Muzny D, Kang H, Lee J, Tamboli P, Reuter V, Shelley CS, Kaipparettu BA, Bottaro DP, Godwin AK, Gibbs RA, Getz G, Kucherlapati R, Park PJ, Sander C, Henske EP, Zhou JH, Kwiatkowski DJ, Ho TH, Choueiri TK, Hsieh JJ, Akbani R, Mills GB, Hakimi AA, Wheeler DA, Creighton CJ.

Cell Rep. 2016 Mar 15;14(10):2476-89. doi: 10.1016/j.celrep.2016.02.024. Epub 2016 Mar 3.

15.

Stable Ectopic Expression of ST6GALNAC5 Induces Autocrine MET Activation and Anchorage-Independence in MDCK Cells.

Chu C, Bottaro DP, Betenbaugh MJ, Shiloach J.

PLoS One. 2016 Feb 5;11(2):e0148075. doi: 10.1371/journal.pone.0148075. eCollection 2016.

16.

Imaging the Met Receptor Tyrosine Kinase (Met) and Assessing Tumor Responses to a Met Tyrosine Kinase Inhibitor in Human Xenograft Mouse Models with a [99mTc] (AH-113018) or Cy 5** (AH-112543) Labeled Peptide.

Jagoda EM, Bhattacharyya S, Kalen J, Riffle L, Leeder A, Histed S, Williams M, Wong KJ, Xu B, Szajek LP, Elbuluk O, Cecchi F, Raffensperger K, Golla M, Bottaro DP, Choyke P.

Mol Imaging. 2015;14:499-515.

PMID:
26461980
17.

Erratum to: A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.

Shapiro GI, McCallum S, Adams LM, Sherman L, Weller S, Swann S, Keer H, Miles D, Müller T, Rabe DC, Cecchi F, Bottaro DP, LoRusso P.

Invest New Drugs. 2015 Dec;33(6):1292. doi: 10.1007/s10637-015-0287-6. No abstract available.

PMID:
26407571
18.

Expression array analysis of the hepatocyte growth factor invasive program.

Cecchi F, Lih CJ, Lee YH, Walsh W, Rabe DC, Williams PM, Bottaro DP.

Clin Exp Metastasis. 2015 Oct;32(7):659-76. doi: 10.1007/s10585-015-9735-0. Epub 2015 Aug 1.

PMID:
26231668
19.

Characterization of HGF/Met Signaling in Cell Lines Derived From Urothelial Carcinoma of the Bladder.

Lee YH, Apolo AB, Agarwal PK, Bottaro DP.

Cancers (Basel). 2014 Nov 25;6(4):2313-29. doi: 10.3390/cancers6042313.

20.

Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladder.

McNeil BK, Sorbellini M, Grubb RL 3rd, Apolo A, Cecchi F, Athauda G, Cohen B, Giubellino A, Simpson H, Agarwal PK, Coleman J, Getzenberg RH, Netto GJ, Shih J, Linehan WM, Pinto PA, Bottaro DP.

J Transl Med. 2014 Oct 21;12:199. doi: 10.1186/1479-5876-12-199.

21.

Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers.

Kauffman EC, Ricketts CJ, Rais-Bahrami S, Yang Y, Merino MJ, Bottaro DP, Srinivasan R, Linehan WM.

Nat Rev Urol. 2014 Aug;11(8):465-75. doi: 10.1038/nrurol.2014.162. Epub 2014 Jul 22. Review.

22.

Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue.

Catenacci DV, Liao WL, Thyparambil S, Henderson L, Xu P, Zhao L, Rambo B, Hart J, Xiao SY, Bengali K, Uzzell J, Darfler M, Krizman DB, Cecchi F, Bottaro DP, Karrison T, Veenstra TD, Hembrough T, Burrows J.

PLoS One. 2014 Jul 1;9(7):e100586. doi: 10.1371/journal.pone.0100586. eCollection 2014.

23.

Synergistic signaling of tumor cell invasiveness by hepatocyte growth factor and hypoxia.

Lee YH, Morrison BL, Bottaro DP.

J Biol Chem. 2014 Jul 25;289(30):20448-61.

24.

Synergistic anti-leukemic activity of imatinib in combination with a small molecule Grb2 SH2 domain binding antagonist.

Zhang M, Luo Z, Liu H, Croce CM, Burke TR Jr, Bottaro DP.

Leukemia. 2014 Apr;28(4):948-51. doi: 10.1038/leu.2013.323. Epub 2013 Oct 31. No abstract available.

25.

Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer.

Shah MA, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP.

PLoS One. 2013;8(3):e54014. doi: 10.1371/journal.pone.0054014. Epub 2013 Mar 14.

26.

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.

Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH, Laubscher KH, Sherman L, McDermott DF, Haas NB, Flaherty KT, Ross R, Eisenberg P, Meltzer PS, Merino MJ, Bottaro DP, Linehan WM, Srinivasan R.

J Clin Oncol. 2013 Jan 10;31(2):181-6. doi: 10.1200/JCO.2012.43.3383. Epub 2012 Dec 3.

27.

Novel antagonists of heparin binding growth factors.

Cecchi F, Bottaro DP.

Oncotarget. 2012 Sep;3(9):911-2.

28.

Inhibition of hypoxia inducible factor-2 transcription: isolation of active modulators from marine sponges.

McKee TC, Rabe D, Bokesch HR, Grkovic T, Whitson EL, Diyabalanage T, Van Wyk AW, Marcum SR, Gardella RS, Gustafson KR, Linehan WM, McMahon JB, Bottaro DP.

J Nat Prod. 2012 Sep 28;75(9):1632-6. Epub 2012 Aug 28.

29.

Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab.

Jagoda EM, Lang L, Bhadrasetty V, Histed S, Williams M, Kramer-Marek G, Mena E, Rosenblum L, Marik J, Tinianow JN, Merchant M, Szajek L, Paik C, Cecchi F, Raffensperger K, Jose-Dizon JM, Bottaro DP, Choyke P.

J Nucl Med. 2012 Oct;53(10):1592-600. doi: 10.2967/jnumed.111.102293. Epub 2012 Aug 23.

30.

Heparin inhibits Hepatocyte Growth Factor induced motility and invasion of hepatocellular carcinoma cells through early growth response protein 1.

Ozen E, Gozukizil A, Erdal E, Uren A, Bottaro DP, Atabey N.

PLoS One. 2012;7(8):e42717. doi: 10.1371/journal.pone.0042717. Epub 2012 Aug 13.

31.

Targeted disruption of heparan sulfate interaction with hepatocyte and vascular endothelial growth factors blocks normal and oncogenic signaling.

Cecchi F, Pajalunga D, Fowler CA, Uren A, Rabe DC, Peruzzi B, Macdonald NJ, Blackman DK, Stahl SJ, Byrd RA, Bottaro DP.

Cancer Cell. 2012 Aug 14;22(2):250-62. doi: 10.1016/j.ccr.2012.06.029.

32.

Targeting the HGF/Met signaling pathway in cancer therapy.

Cecchi F, Rabe DC, Bottaro DP.

Expert Opin Ther Targets. 2012 Jun;16(6):553-72. doi: 10.1517/14728222.2012.680957. Epub 2012 Apr 25. Review.

33.

A new hypoxia inducible factor-2 inhibitory pyrrolinone alkaloid from roots and stems of Piper sarmentosum.

Bokesch HR, Gardella RS, Rabe DC, Bottaro DP, Linehan WM, McMahon JB, McKee TC.

Chem Pharm Bull (Tokyo). 2011;59(9):1178-9.

34.

Application of ring-closing metathesis to Grb2 SH3 domain-binding peptides.

Liu F, Giubellino A, Simister PC, Qian W, Giano MC, Feller SM, Bottaro DP, Burke TR Jr.

Biopolymers. 2011;96(6):780-8. doi: 10.1002/bip.21692.

35.

Identification and evaluation of soft coral diterpenes as inhibitors of HIF-2α induced gene expression.

Grkovic T, Whitson EL, Rabe DC, Gardella RS, Bottaro DP, Linehan WM, McMahon JB, Gustafson KR, McKee TC.

Bioorg Med Chem Lett. 2011 Apr 1;21(7):2113-5. doi: 10.1016/j.bmcl.2011.01.127. Epub 2011 Feb 23.

36.

The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer.

Cecchi F, Rabe DC, Bottaro DP.

Curr Signal Transduct Ther. 2011;6(2):146-151.

37.

A tandem repeat of a fragment of Listeria monocytogenes internalin B protein induces cell survival and proliferation.

Mungunsukh O, Lee YH, Marquez AP, Cecchi F, Bottaro DP, Day RM.

Am J Physiol Lung Cell Mol Physiol. 2010 Dec;299(6):L905-14. doi: 10.1152/ajplung.00094.2010. Epub 2010 Oct 1.

38.

Gab1 mediates hepatocyte growth factor-stimulated mitogenicity and morphogenesis in multipotent myeloid cells.

Felici A, Giubellino A, Bottaro DP.

J Cell Biochem. 2010 Oct 1;111(2):310-21. doi: 10.1002/jcb.22695.

39.

Targeting the HGF/Met signalling pathway in cancer.

Cecchi F, Rabe DC, Bottaro DP.

Eur J Cancer. 2010 May;46(7):1260-70. doi: 10.1016/j.ejca.2010.02.028. Epub 2010 Mar 19. Review.

40.

Molecular diagnosis and therapy of kidney cancer.

Linehan WM, Bratslavsky G, Pinto PA, Schmidt LS, Neckers L, Bottaro DP, Srinivasan R.

Annu Rev Med. 2010;61:329-43. doi: 10.1146/annurev.med.042808.171650. Review.

41.

Urine analysis and protein networking identify met as a marker of metastatic prostate cancer.

Russo AL, Jedlicka K, Wernick M, McNally D, Kirk M, Sproull M, Smith S, Shankavaram U, Kaushal A, Figg WD, Dahut W, Citrin D, Bottaro DP, Albert PS, Tofilon PJ, Camphausen K.

Clin Cancer Res. 2009 Jul 1;15(13):4292-8. doi: 10.1158/1078-0432.CCR-09-0599. Epub 2009 Jun 23.

42.

Targeting the Met signaling pathway in renal cancer.

Giubellino A, Linehan WM, Bottaro DP.

Expert Rev Anticancer Ther. 2009 Jun;9(6):785-93. doi: 10.1586/era.09.43. Review.

43.

Identification of Shc Src homology 2 domain-binding peptoid-peptide hybrids.

Choi WJ, Kim SE, Stephen AG, Weidlich I, Giubellino A, Liu F, Worthy KM, Bindu L, Fivash MJ, Nicklaus MC, Bottaro DP, Fisher RJ, Burke TR Jr.

J Med Chem. 2009 Mar 26;52(6):1612-8. doi: 10.1021/jm800789h.

44.

Directed discovery of agents targeting the Met tyrosine kinase domain by virtual screening.

Peach ML, Tan N, Choyke SJ, Giubellino A, Athauda G, Burke TR Jr, Nicklaus MC, Bottaro DP.

J Med Chem. 2009 Feb 26;52(4):943-51. doi: 10.1021/jm800791f.

45.

Selectivity and mechanism of action of a growth factor receptor-bound protein 2 SRC homology 2 domain binding antagonist.

Giubellino A, Shi ZD, Jenkins LM, Worthy KM, Bindu LK, Athauda G, Peruzzi B, Fisher RJ, Appella E, Burke TR, Bottaro DP.

J Med Chem. 2008 Dec 11;51(23):7459-68. doi: 10.1021/jm800523u.

46.

VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma.

Linehan WM, Rubin JS, Bottaro DP.

Int J Biochem Cell Biol. 2009 Apr;41(4):753-6. doi: 10.1016/j.biocel.2008.09.024. Epub 2008 Oct 2. Review.

47.

Grb2 signaling in cell motility and cancer.

Giubellino A, Burke TR Jr, Bottaro DP.

Expert Opin Ther Targets. 2008 Aug;12(8):1021-33. doi: 10.1517/14728222.12.8.1021 . Review.

48.

Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1.

Lee SJ, Lattouf JB, Xanthopoulos J, Linehan WM, Bottaro DP, Vasselli JR.

Eur Urol. 2008 Oct;54(4):845-53. doi: 10.1016/j.eururo.2008.01.010. Epub 2008 Jan 16.

49.

Loss of secreted frizzled-related protein-1 expression in renal cell carcinoma reveals a critical tumor suppressor function.

Rubin JS, Bottaro DP.

Clin Cancer Res. 2007 Aug 15;13(16):4660-3. No abstract available.

50.

Inhibition of tumor metastasis by a growth factor receptor bound protein 2 Src homology 2 domain-binding antagonist.

Giubellino A, Gao Y, Lee S, Lee MJ, Vasselli JR, Medepalli S, Trepel JB, Burke TR Jr, Bottaro DP.

Cancer Res. 2007 Jul 1;67(13):6012-6.

Supplemental Content

Loading ...
Support Center